{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:54:39Z","timestamp":1792079679073,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94894-2","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T03:46:57Z","timestamp":1742528817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of anti-inflammatory and anti-angiogenic effects of JAK inhibitors in IL-6 and TNF\u03b1-stimulated fibroblast-like synoviocytes derived from patients with RA"],"prefix":"10.1038","volume":"15","author":[{"given":"Yoshihito","family":"Suda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemmei","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Anjiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kamenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tsubosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsumiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"94894_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298\u2013307 (2011).","journal-title":"Nature"},{"key":"94894_CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","volume":"18","author":"HA Elshabrawy","year":"2015","unstructured":"Elshabrawy, H. A. et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18, 433\u2013448 (2015).","journal-title":"Angiogenesis"},{"key":"94894_CR3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1161\/01.CIR.0000128595.79378.FA","volume":"109","author":"DW Losordo","year":"2004","unstructured":"Losordo, D. W. & Dimmeler, S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. Circulation 109, 2487\u20132491 (2004).","journal-title":"Circulation"},{"key":"94894_CR4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"94894_CR5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.27287","volume":"62","author":"A Kennedy","year":"2010","unstructured":"Kennedy, A. et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum. 62, 711\u2013721 (2010).","journal-title":"Arthritis Rheum."},{"key":"94894_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2009.02.002","volume":"51","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz, Z. & Koch, A. E. Angiogenesis and its targeting in rheumatoid arthritis. Vascul. Pharmacol. 51, 1\u20137 (2009).","journal-title":"Vascul. Pharmacol."},{"key":"94894_CR7","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan, F. M. & McInnes, I. B. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118, 3537\u20133545 (2008).","journal-title":"J. Clin. Invest."},{"key":"94894_CR8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242\u2013248 (2000).","journal-title":"Nature"},{"key":"94894_CR9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D","volume":"41","author":"AE Koch","year":"1998","unstructured":"Koch, A. E. Review: Angiogenesis\u2014Implications for rheumatoid arthritis. Arthritis Rheum. 41, 951\u2013962 (1998).","journal-title":"Arthritis Rheum."},{"key":"94894_CR10","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4049\/jimmunol.152.8.4149","volume":"152","author":"AE Koch","year":"1994","unstructured":"Koch, A. E. et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149\u20134156 (1994).","journal-title":"J. Immunol."},{"key":"94894_CR11","doi-asserted-by":"crossref","first-page":"119034","DOI":"10.1016\/j.lfs.2021.119034","volume":"269","author":"F Moadab","year":"2021","unstructured":"Moadab, F., Khorramdelazad, H. & Abbasifard, M. Role of CCL2\/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches. Life Sci. 269, 119034 (2021).","journal-title":"Life Sci."},{"key":"94894_CR12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/ar401","volume":"4","author":"MP Vincenti","year":"2002","unstructured":"Vincenti, M. P. & Brinckerhoff, C. E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: Integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 4, 157\u2013164 (2002).","journal-title":"Arthritis Res."},{"key":"94894_CR13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud, C. J. The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 10, 117\u2013127 (2018).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"94894_CR14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen, S. B. et al. Safety profile of Upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme. Ann. Rheum. Dis. 80, 304\u2013311 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"94894_CR15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann, R. et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 69, 506\u2013517 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"94894_CR16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese, M. C. et al. Effect of filgotinib versus placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial. Jama 322, 315\u2013325 (2019).","journal-title":"Jama"},{"key":"94894_CR17","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377\u20132386 (2014).","journal-title":"N. Engl. J. Med."},{"key":"94894_CR18","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi, T. et al. Efficacy and safety of Peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann. Rheum. Dis. 78, 1305\u20131319 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"94894_CR19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fped.2018.00358","volume":"6","author":"LA Barreiros","year":"2018","unstructured":"Barreiros, L. A. et al. Corrigendum: A novel homozygous JAK3 mutation leading to T-B\u2009+\u2009NK- SCID in two Brazilian patients. Front. Pediatr. 6, 358 (2018).","journal-title":"Front. Pediatr."},{"key":"94894_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kel065","volume":"45","author":"LC Huber","year":"2006","unstructured":"Huber, L. C. et al. Synovial fibroblasts: Key players in rheumatoid arthritis. Rheumatology 45, 669\u2013675 (2006).","journal-title":"Rheumatology"},{"key":"94894_CR21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12860-020-00317-7","volume":"21","author":"A Valin","year":"2020","unstructured":"Valin, A. et al. IL6\/sIL6R regulates TNF\u03b1-inflammatory response in synovial fibroblasts through modulation of transcriptional and post-transcriptional mechanisms. BMC Mol. Cell. Biol. 21, 74 (2020).","journal-title":"BMC Mol. Cell. Biol."},{"key":"94894_CR22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: From bench to clinic. Signal. Transduct. Target Ther. 6, 402 (2021).","journal-title":"Signal. Transduct. Target Ther."},{"key":"94894_CR23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon, L. S. et al. The Jak\/STAT pathway: A focus on pain in rheumatoid arthritis. Semin. Arthritis Rheum. 51, 278\u2013284 (2021).","journal-title":"Semin Arthritis Rheum."},{"key":"94894_CR24","doi-asserted-by":"crossref","first-page":"e0180922","DOI":"10.1371\/journal.pone.0180922","volume":"12","author":"KR Gillinder","year":"2017","unstructured":"Gillinder, K. R. et al. Direct targets of pSTAT5 signalling in erythropoiesis. PloS One 12, e0180922 (2017).","journal-title":"PloS One"},{"key":"94894_CR25","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Prim. 4, 18001 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"94894_CR26","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon, S. Tofacitinib: A review in rheumatoid arthritis. Drugs 77, 1987\u20132001 (2017).","journal-title":"Drugs"},{"key":"94894_CR27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama, Z. T. & Scott, L. J. Baricitinib: A review in rheumatoid arthritis. Drugs 78, 761\u2013772 (2018).","journal-title":"Drugs"},{"key":"94894_CR28","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s10067-024-07142-9","volume":"43","author":"K Anjiki","year":"2024","unstructured":"Anjiki, K. et al. JAK inhibitors inhibit angiogenesis by reducing VEGF production from rheumatoid arthritis-derived fibroblast-like synoviocytes. Clin. Rheumatol. 43, 3525\u20133536 (2024).","journal-title":"Clin. Rheumatol."},{"key":"94894_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett, F. C. et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315\u2013324 (1988).","journal-title":"Arthritis Rheum."},{"key":"94894_CR30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/art.1780310803","volume":"31","author":"M Rooney","year":"1988","unstructured":"Rooney, M. et al. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 31, 956\u2013963 (1988).","journal-title":"Arthritis Rheum."},{"key":"94894_CR31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00296-009-1158-2","volume":"30","author":"H Yamanaka","year":"2010","unstructured":"Yamanaka, H., Goto, K. & Miyamoto, K. Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy. Rheumatol. Int. 30, 409\u2013413 (2010).","journal-title":"Rheumatol. Int."},{"key":"94894_CR32","doi-asserted-by":"crossref","first-page":"12516","DOI":"10.1038\/s41598-021-92055-9","volume":"11","author":"Y Takashima","year":"2021","unstructured":"Takashima, Y. et al. Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1\u03b2-induced inflammation. Sci. Rep. 11, 12516 (2021).","journal-title":"Sci. Rep."},{"key":"94894_CR33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."},{"key":"94894_CR34","doi-asserted-by":"crossref","first-page":"1387585","DOI":"10.3389\/fphar.2024.1387585","volume":"15","author":"W Cai","year":"2024","unstructured":"Cai, W., Tong, R., Sun, Y., Yao, Y. & Zhang, J. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: A systematic review and network meta-analysis of randomized controlled trials. Front. Pharmacol. 15, 1387585 (2024).","journal-title":"Front. Pharmacol."},{"key":"94894_CR35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/imt-2018-0178","volume":"11","author":"J Jegatheeswaran","year":"2019","unstructured":"Jegatheeswaran, J., Turk, M. & Pope, J. E. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: A systemic literature review. Immunotherapy 11, 737\u2013754 (2019).","journal-title":"Immunotherapy"},{"key":"94894_CR36","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1007\/s12325-020-01303-3","volume":"37","author":"J Pope","year":"2020","unstructured":"Pope, J. et al. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: A network meta-analysis. Adv. Ther. 37, 2356\u20132372 (2020).","journal-title":"Adv. Ther."},{"key":"94894_CR37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo, S., Nakayamada, S. & Tanaka, Y. JAK inhibitors for rheumatoid arthritis. Expert Opin. Investig. Drugs 32, 333\u2013344 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"94894_CR38","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/art.37691","volume":"64","author":"A Yarilina","year":"2012","unstructured":"Yarilina, A., Xu, K., Chan, C. & Ivashkiv, L. B. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 64, 3856\u20133866 (2012).","journal-title":"Arthritis Rheum."},{"key":"94894_CR39","doi-asserted-by":"crossref","unstructured":"Kong, D. H., Kim, Y. K., Kim, M. R., Jang, J. H. & Lee, S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int. J. Mol. Sci. 19 (2018).","DOI":"10.3390\/ijms19041057"},{"key":"94894_CR40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/mol.65.2.389","volume":"65","author":"JH Distler","year":"2004","unstructured":"Distler, J. H. et al. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. Mol. Pharmacol. 65, 389\u2013399 (2004).","journal-title":"Mol. Pharmacol."},{"key":"94894_CR41","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington, R., Al Nokhatha, S. A. & Conway, R. JAK inhibitors in rheumatoid arthritis: An evidence-based review on the emerging clinical data. J. Inflamm. Res. 13, 519\u2013531 (2020).","journal-title":"J. Inflamm. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94894-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T03:48:24Z","timestamp":1742528904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94894-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94894"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94894-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9736"}}